81 terminated. 81 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 81 | Terminated 81 |
| Phase 2 | 4 | Terminated 4 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG) - Severe Aplastic Anemia | Phase 3 | Terminated | Boston Children's Hospital | 53 | 2023-01-25 | 2026-10-19 |
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| Voxelotor Neurocognitive Function Study Voxelotor Only Product in Oral Dose Form, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 1 | 2022-06-24 | 2024-05-02 |
| THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis | Phase 3 | Terminated | University Health Network, Toronto | 4 | 2022-06-07 | 2025-03-19 |
| Resolution of Sickle Cell Leg Ulcers With Voxelotor Voxelotor Oral Tablet, Placebo - Sickle Cell Disease, Leg Ulcers | Phase 3 | Terminated | Pfizer | 88 | 2022-05-30 | 2025-07-09 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults. Sufentanil, EMONO - Sickle Cell Crisis | Phase 3 | Terminated | University Hospital, Bordeaux | 115 | 2021-07-20 | 2026-06-22 |
| Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease Voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 236 | 2020-11-11 | 2026-03-10 |
| Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome | Phase 3 | Terminated | Dr. med. Mahir Karakas | 68 | 2020-02-21 | 2022-05-24 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. REGN3918 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2019-12-03 | 2023-06-12 |
| Open-Label Extension of Voxelotor Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 162 | 2019-11-18 | 2025-11-13 |
| Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease Patient-Specific Protocol, Weight-based Protocol, Morphine - Sickle Cell Disease | Phase 3 | Terminated | Duke University | 328 | 2019-08-13 | 2023-07-03 |
| Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS INM004, Placebo - Bloody Diarrhea, STEC, Unspecified | Phase 2 / Phase 3 | Terminated | Inmunova S.A. | 11 | 2019-07-17 | 2023-07-19 |
| Iron in Patients With Cardiovascular Disease Ferric carboxymaltose, Saline - Cardiovascular Diseases, Anemia, Iron-deficiency | Phase 3 | Terminated | Dr. med. Mahir Karakas | 8 | 2019-02-28 | 2023-12-27 |
| Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Ticagrelor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | AstraZeneca | 193 | 2018-09-26 | 2021-04-09 |
| Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 179 | 2018-06-06 | 2025-11-18 |
| Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis Denosumab 60 MG/ML Prefilled Syringe, Zoledronic Acid 5Mg/Bag 100Ml Inj - Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis | Phase 3 | Terminated | Hamad Medical Corporation | 17 | 2018-05-14 | 2019-12-12 |
Showing 20 of 81. Sign in to see all of them.
Anemia, Sickle Cell (28) · Vaso-Occlusive Crises (8) · Anemia, Iron-Deficiency (7) · Neoplasms (6) · Hematologic Diseases (5) · Renal Insufficiency, Chronic (5) · Hypertension, Pulmonary (4) · Iron Deficiencies (4) · Myelodysplastic Syndromes (4) · Anemia, Aplastic (3) · Hemoglobinuria, Paroxysmal (3) · Acute Chest Syndrome (2) · Agnosia (2) · Anemia, Refractory, with Excess of Blasts (2)
Hemic and Lymphatic Diseases (81) · Hematologic Diseases (76) · Anemia, Hemolytic (37) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (32) · Anemia, Hemolytic, Congenital (31) · Genetic Diseases, Inborn (31) · Hemoglobinopathies (31) · Pathological Conditions, Signs and Symptoms (14) · Nutritional and Metabolic Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (11) · Metabolic Diseases (11) · Urogenital Diseases (11) · Bone Marrow Diseases (10) · Female Urogenital Diseases (10)
Epoetin Alfa (11) · Darbepoetin alfa (6) · continuous erythropoietin receptor activator (6) · ferric carboxymaltose (4) · voxelotor (4) · Bosentan (3) · Ferrosoferric Oxide (3) · Hydroxyurea (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Erythrocyte Transfusion (2) · Iron (2) · Saline Solution (2) · Sodium Chloride (2) · Sugars (2) · ferrous fumarate (2)
Pfizer (8) · Hoffmann-La Roche (6) · Amgen (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · AMAG Pharmaceuticals, Inc. (3) · Actelion (3) · Children's Hospital Medical Center, Cincinnati (3) · CTI BioPharma (2) · Dr. med. Mahir Karakas (2) · Icagen (2) · Ortho Biotech Products, L.P. (2) · Regeneron Pharmaceuticals (2) · Repros Therapeutics Inc. (2) · AGO Study Group (1) · AKARI Therapeutics (1)
United States (40) · United Kingdom (17) · Germany (15) · France (14) · Canada (13) · Italy (11) · Brazil (10) · Belgium (9) · Kenya (7) · Poland (7) · Russia (7) · Czechia (6) · Lebanon (6) · Netherlands (6) · Nigeria (6)
Russell E. Ware, MD, PhD (3) · Mahir Karakas, MD (2) · Anders Berggren, MD, PhD (1) · Andre van As, MD, PhD (1) · Andrea Vetter, Dr. (1) · Beth Ziemba (1) · Bjorn Backe, MD PhD (1)
PMID 36791280, PMID 20175775, PMID 33275766, PMID 34219224, PMID 40277027, PMID 12966125, PMID 15050885, PMID 16553139, PMID 17312332, PMID 17985376, PMID 17999759, PMID 18477354, PMID 21233311, PMID 21826782, PMID 21848879, PMID 22318199, PMID 23539110, PMID 23861242, PMID 24914136, PMID 26414435, PMID 26644172, PMID 26670617, PMID 31072967, PMID 31446143, PMID 31582549, PMID 32444411, PMID 33455926, PMID 33781988, PMID 33783815, PMID 34551507, PMID 34724251, PMID 35849650, PMID 35981565, PMID 37524101, PMID 38171625, PMID 38689774, PMID 39154808, PMID 39400386, PMID 41249873, PMID 42316774, PMID 42665434
2019 (4), 1UG3HL157564-01A1 (1), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2017 (1), R01DK052147 (1), R01HL095647 (1), R01HL098239 (1), U01HL078787 (1), U10HL083721 (1), U24HL137907 (1), U24HL157560 (1), U54HL070587 (1)